| Literature DB >> 31193272 |
Jingjing Fang1, Xinhong Xu1, Lu Jiang1, Jiangbo Qiao2, Hongyuan Zhou1, Kexian Li1.
Abstract
The present study was carried out to evaluate the hematotoxicity and respiratory toxicity of methyl mercaptan in Sprague-Dawley rats. A dynamic exposure methodology was adopted in this study following 7 days of exposure by repeated inhalation. The concentration of methyl mercaptan used in the exposure was 0.5 ppm and the exposure time was 6 h/day for 7 days. After exposure, the rats were sacrificed to collect lung tissue and blood samples. Routine blood and serum biochemistry were conducted. Morphological injury of lung tissue was detected by hematoxylin and eosin staining. Decreased food consumption and body weight gain in both sexes were noted in the exposure group compared with the control group. Several significant changes in hematological parameters were observed. The results showed that the blood urea nitrogen (UREA) levels and superoxide dismutase (SOD) values were significantly decreased in exposed male rats. Malondialdehyde (MDA) in lung tissue was significantly increased in both males and females in the exposed group. In the histopathological examination of lung tissue, terminal bronchiole constriction, alveolar congestion, and erythrocyte exudation were observed, suggesting that the lungs may be target organs after inhaling methyl mercaptan and workers exposed to this concentration may cause some pulmonary stimulation and injury.Entities:
Keywords: Hematotoxicity; Methyl mercaptan; Odor compound; Pulmonary toxicity; Short-term exposure
Year: 2019 PMID: 31193272 PMCID: PMC6525278 DOI: 10.1016/j.toxrep.2019.05.006
Source DB: PubMed Journal: Toxicol Rep ISSN: 2214-7500
Fig. 1The inhalation exposure chamber system.
Nomenclature and abbreviation of laboratory tests.
| Nomenclature | |||
|---|---|---|---|
| Hematological parameters | Serum biochemical parameters | ||
| WBC | White blood cell (109/ L) | ||
| RBC | Red blood cell (1012/ L) | STP | Serum total protein(g/dL) |
| HGB | Hemoglobin (g/L) | ALB | Albumin(g/dL) |
| MCV | Mean corpuscular volume (fL) | A/G | Albumin/Globin |
| MCH | Mean corpuscular hemoglobin(pg) | TBIL | Total bilirubin (mg/dL) |
| MCHC | Mean corpuscular hemoglobin concentration (g/L) | GGT | Gamma-glutamyl transpeptidase (IU/L) |
| PLT | Platelets (109/L) | DBIL | Direct bilirubin (mg/dL) |
| LYMPH | Lymphocytes (%) | ALT | Alanine aminotransferase (IU/L) |
| MONO | Monocytes (%) | ALP | Alkaline phosphatase(IU/L) |
| NEUT | Neutrophils (%) | ASTm | Aspartate aminotransferase isoenzyme (IU/L) |
| EOS | Eosinophils (%) | AST | Aspartate aminotransferase (IU/L) |
| BASO | Basophils (%) | LDH | Lactate dehydrogenase (IU/L) |
| RDW-C | Red cell distribution width-CV(%) | ||
| RDW-S | Red cell distribution width-SD(fL) | CREA | Creatinine (mg/dL) |
| PDW | Platelets distribution width(%) | UREA | Blood urea nitrogen (mmol/dL) |
| MPV | Mean platelets volume(fL) | GLU | Glucose (mg/dL) |
| PCT | Plateletcrit(%) | UA | Uric acid (μmol/dL) |
| HCT | Hematocrit(%) | RBP | Retinol binding protein (mg/L) |
| CysC | Cystatin C (mg/L) | ||
| MDA | malondialdehyde (nmol/mg) | ||
| CK | Creatine kinase (IU/L) | ||
| CK-MB | Creatine kinase isoenzymes (IU/L) | ||
| ACE | Angiotensin converting enzyme (IU/L) | ||
| TT3 | Total triiodothyronine (ng/dL) | ||
| TT4 | Total thyronine (ng/dL) | ||
| FT3 | Free triiodothyronine (ng/dL) | ||
| FT4 | Free thyronine (ng/dL) | ||
| SOD | Superoxide dismutase (IU/L) | ||
Pathology score standard of lung tissue.
| score | A Infiltrative around bronchioles and bronchi | B Exudation in bronchioles and bronchi | C Infiltration around blood vessel | D Edema | E Atelectasis |
|---|---|---|---|---|---|
| 0 | None | None | None | None | None |
| 1 | <25% | <25% | <10% | Few | <25% |
| 2 | 25-50% | 25-50% | 10%-50% | Slightly | 25-50% |
| 3 | 50-75% | 50-75% | 50-75% | Severely | 50-75% |
| 4 | >75% | >75% | >75% | Completely | >75% |
Score = A+B + C+D + E.
Fig. 2Body weight changes of the rats exposed to methyl mercaptan.
Hematological parameters of the control and exposure groups.
| Parameter | Group | |||
|---|---|---|---|---|
| Control-male | Control-female | Exposure-male | Exposure-female | |
| WBC (109/L) | 7.3 ± 2.6 | 6.6 ± 1.2 | 5.6 ± 4.8 | 5.3 ± 3.0 |
| RBC (1012/L) | 7.2 ± 0.1 | 6.5 ± 0.3 | 7.9 ± 1.0 | 6.3 ± 0.5 |
| HGB (g/dL) | 137 ± 4 | 137 ± 4 | 149 ± 18 | 123 ± 8 |
| HCT (%) | 42.8 ± 1.8 | 38.2 ± 1.9 | 46.7 ± 5.2 | 37.1 ± 1.8 |
| MCV (fL) | 59.3 ± 2.8 | 58.7 ± 1.7 | 59.3 ± 0.6 | 59.2 ± 1.8 |
| MCH (pg) | 19.0 ± 0.6 | 19.7 ± 0.6 | 18.9 ± 0.2 | 19.7 ± 0.3 |
| MCHC (g/dL) | 321.3 ± 4.9 | 335.0 ± 7.5 | 318.5 ± 3.5 | 333.5 ± 4.9 |
| PLT (109/L) | 992 ± 94 | 992 ± 62 | 1137 ± 203 | 962 ± 11 |
| NEUT (%) | 81.1 ± 1.4 | 83.6 ± 2.1 | 82.3 ± 1.3 | 82.3 ± 5.1 |
| LYMPH (%) | 3.9 ± 1.3 | 2.2 ± 0.8 | 3.5 ± 0.9 | 2.3 ± 0.1 |
| MONO (%) | 14.5 ± 1.3 | 13.9 ± 1.2 | 13.8 ± 1.4 | 14.8 ± 5.0 |
| EOS (%) | 0.3 ± 0.3 | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.3 ± 0.1 |
| BASO (%) | 0.2 ± 0.1 | 0.1 ± 0.1 | 0.2 ± 0.1 | 0.4 ± 0.1 |
| RDW-C(%) | 12.3 ± 0.7 | 11.4 ± 0.5 | 12.8 ± 01. | 12.8 ± 0.6 |
| RDW-S(fL) | 30.0 ± 0.6 | 27.7 ± 1.4 | 31.2±.2 | 31.4 ± 2.7 |
| PDW(%) | 14.7 ± 0.1 | 14.7 ± 0.1 | 15.0 ± 0.1* | 14.8 ± 0.1 |
| MPV(fL) | 5.7 ± 0.1 | 5.6 ± 0.1 | 5.9 ± 0.1 | 5.8 ± 0.1 |
| PCT(%) | 0.6 ± 0.1 | 0.5 ± 0.04 | 0.7 ± 0.1 | 0.6 ± 0.01 |
Values represent the mean ± SEM, n = 15. Control-male vs. Exposure-male, Control-female vs. Exposure-female, * P < 0.05. * *P < 0.01.
Serum and tissue biochemical values of the control and exposure groups.
| Sample | Parameter | Group | |||
|---|---|---|---|---|---|
| Control -male | Control -female | Exposure -male | Exposure -female | ||
| Serum | |||||
| STP(g/dL) | 49 ± 2 | 49 ± 4 | 55 ± 3 | 54 ± 3 | |
| ALB(g/dL) | 23.2 ± 0.8 | 24.3 ± 1.2 | 25.6 ± 1.5** | 26.5 ± 0.7 | |
| A/G | 0.9 ± 0.1 | 1.0 ± 0.1 | 0.9 ± 0.0 | 1.0 ± 0.1 | |
| TBIL(mg/dL) | 1.2 ± 0.4 | 0.6 ± 0.7 | 0.8 ± 0.6 | 1.0 ± 0.3 | |
| DBIL(mg/dL) | 0.4 ± 0.3 | 0.1 ± 0.6 | 0.4 ± 0.3 | 0.1 ± 0.1 | |
| ALT(IU/L) | 64 ± 8 | 65 ± 7 | 42 ± 9** | 53 ± 1 | |
| ALP(IU/L) | 282 ± 24 | 163 ± 5 | 225 ± 41 | 158 ± 7* | |
| GGT(IU/L) | 0.4 ± 1.1 | 1.3 ± 1.5 | 0.8 ± 0.4 | 1.5 ± 0.7 | |
| ASTm(IU/L) | 45 ± 8 | 29 ± 12 | 26 ± 14* | 42 ± 4 | |
| AST(IU/L) | 165 ± 36. | 139 ± 27 | 144 ± 41 | 171 ± 18 | |
| LDH(IU/L) | 1094 ± 276 | 497 ± 222 | 650 ± 228* | 786 ± 98 | |
| CREA (mg/dL) | 19 ± 5 | 32 ± 1 | 24 ± 2 | 29 ± 1* | |
| UREA(mmol/dL) | 6.6 ± 0.3 | 5.4 ± 0.2 | 6.1 ± 0.5 | 7.4 ± 0.1** | |
| GLU (mg/dL) | 17.4 ± 2.0 | 21.1 ± 8.8 | 14.8 ± 3.3 | 17.7 ± 1.3 | |
| UA (μmol/dL) | 225 ± 22 | 211 ± 144 | 149 ± 22* | 1 01 ± 9 | |
| RBP(mg/L) | 0.4 ± 1.9 | 1.7 ± 2.1 | 1.2 ± 2.0 | 3.0 ± 1.4 | |
| CysC(mg/L) | 0.19 ± 0.01 | 0.18 ± 0.01 | 0.18 ± 0.01 | 0.16 ± 0.07* | |
| CK (IU/L) | 4150 ± 2058 | 2456 ± 1803 | 3184 ± 1528 | ||
| CK-MB (IU/L) | 1030 ± 144 | 526 ± 164 | 968 ± 148 | ||
| ACE (IU/L) | 288 ± 18.0 | 271.7 ± 11.0 | 294.2 ± 15.1 | ||
| TT3 (ng/dL) | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.8 ± 0.0 | 0.8 ± 0.0 | |
| TT4 (ng/dL) | 37.8 ± 5.2 | 40.5 ± 12.6 | 37.2 ± 1.8 | 36.7 ± 0.0 | |
| FT3 (ng/dL) | 3.1 ± 0.4 | 3.1 ± 0.6 | 3.2 ± 0.3 | 2.9 ± 0.0 | |
| FT4 (ng/dL) | 11.2 ± 1.9 | 11.8 ± 1.0 | 12.4 ± 0.9 | 11.6 ± 0.0 | |
| Serum | SOD(IU/L) | 277 ± 36.7 | 149.7 ± 31.5 | 148.2 ± 51.5** | 179.5 ± 31.8 |
| Lung | MDA (nmol/mg) | 27.0 ± 2.8 | 24.8 ± 2.5 | 34.5 ± 4.3* | 31.8 ± 0.1* |
Values represent the mean ± SEM, n = 15. Control-male vs. Exposure-male, Control-female vs. Exposure-female, * P < 0.05. * *P < 0.01.
Fig. 3Histopathology of the lung tissue of control and exposure groups. Hematoxylin and eosin (H&E) stain.
Score of lung tissue pathology (mean ± SEM, n = 15).
| Control-male | Control-female | Exposure-male | Exposure-female | |
|---|---|---|---|---|
| A | 0 | 0 | 0.6 ± 0.5 | 1.2 ± 0.7 |
| B | 0 | 0 | 0.8 ± 0.5 | 1.1 ± 0.4 |
| C | 0.8 ± 0.5 | 0.4 ± 0.1 | 0.4 ± 0.4 | 0.8 ± 0.5 |
| D | 0 | 0 | 0.6 ± 0.4 | 0.6 ± 0.8 |
| E | 0 | 0 | 1.2 ± 0.6 | 1.2 ± 0.5 |
| Score | 0.8 ± 0.5 | 0.4 ± 0.1 | 3.6 ± 2.4* | 4.9 ± 2.9* |
The pathology score standard of lung tissue = A+B + C+D + E, Control-male vs. Exposure-male, Control-female vs. Exposure-female,* P < 0.05.